Cell Therapy Market Synopsis

Cell Therapy Market Size Was Valued at USD 14.6 Billion in 2023, and is Projected to Reach USD 77.6 Billion by 2032, Growing at a CAGR of 20.4% From 2024-2032.

Cell therapy can be described as the process of introducing alive cells into the body of a patient in order to cure or prevent an illness. OLM combines the principles of regenerative medicine with the use of stem cells and other cells from the body to build new tissue or to replace an organ. The purpose of cell therapy is to use living cells to resolve various diseases, repair human body tissues and help resist infections as well as combat illnesses. With the contemporary major branches of cell therapy including oncology, neurodegenerative disorders, and autoimmune diseases, cell therapy has the exact possibilities of altering the course of current day medical practice.

• The cell therapy industry has become one of the most promising and rapidly growing submarkets within the more general field of biotechnology and pharmaceuticals. This is being driven by new developments in regenerative medicine and related cellular technology which has increased research activities towards finding more and diverse utilization for the products. Some of the factors that still drive market growth include; growth in investment on cell centred research, enhancement in manufacturing technologies and rise in chronic diseases that require cellular solutions. In addition, the regulatory authorities of the world have come up with more policies that help in giving easier approvals to cell therapies this also boosts the market. The requirement for patient-specific therapy, especially in cell therapy, also contributes to the development of the cell therapy market.
• This has given rise to higher probability of chronic diseases, increased mankind’s average age, and thereby brought about a greater market for the use of cell therapies as treatments. More and more people with cancer, cardiovascular diseases, and other degenerative diseases have been treated through cell-based therapy. Also, the advancements of the existing technology in the form of CRISPR and gene editing are enabling cell therapy to harness the best of the possibilities in cellular medication that enables targeted cures. Due to the synergy of these factors, the market is expected to achieve favorable growth rates and continue attracting both private and public investments. Therefore, the analysis of the cell therapy market proves it has high potential for growth in the following years due to technology advancements and deeper knowledge of the cellular basis of diseases.

Cell Therapy Market Trend Analysis

Advancements in Personalized Cell Therapy

• A key trend in the development of cell therapy market is the shift in focus on personalized cell therapies. This approach involves developing treatments to fit a patient individually to his/her genetic constitution and environment thus increasing the value of the treatment and reducing side effects. Enhancement of precision medicine has challenged investigators and industries to find ways of using patients’ cells, especially in the case of CAR-T cell therapy needed to treat cancer diseases. The prospective of autologous individualized cell therapies is not only better therapeutic efficacy but also fits into the current trend of medicine – individualized treatment. With advancements in technology also improving the methods of cell processing and manufacturing which are well suited to the development of personalized cell therapy, excelled market growth is expected along with the rising number of clinical trials and approvals that are expected in the next few years.

Expanding Applications in Autoimmune Diseases

• The market for cell treatment is fairly large and especially so in the area of autoimmune diseases. As knowledge of these intricate diseases expands, investigators are venturing through different stem cell approaches to regulate immune reactions and stimulate organism repair work. Thus, autoimmunity, including rheumatoid arthritis, multiple sclerosis and lupus, climbs as the prevalent diseases upgrading the requirement for efficient therapeutic treatments. These unmet needs can be served through cell therapy that can be used to provide solution that can rebalance the immune system and cure symptoms. Furthermore, the progress of manufacturing technologies and the institutional support for cell therapy research will expand the range of opportunity, making the market an exciting area for creating new opportunities to find a solution to chronic autoimmune diseases.

Cell Therapy Market Segment Analysis:

Cell Therapy Market Segmented on the basis of type and End User.

By Type, Autologous Therapies segment is expected to dominate the market during the forecast period

• The autologous therapies segment will have the largest share in cell therapy market during the forecast period for several reasons. Although allogeneic cell therapies involve using third-party cells for the delivery of therapeutic doses of cells, autologous therapies that involve the use of the patient’s own cells do not raise the same issues have been seen with allogeneic transplants despite the fact that autologous cells are harvested, processed, and reinfused for the purpose of treating or preventing a disease or condition in the same person. Such a customized approach means increasing the effectiveness and safety of the treatments, which could explain why patients and doctors could like this model. Furthermore, improvements in technology that enables processing and application of autologous products together with encouraging results derived from clinical practice in various fields make autologous applications popular among clinics. Thus, as new applications for autologous cell therapies being revealed in oncology and regenerative medicine industries this segment is expected to grow continuously occupying considerable market share.

By End User, Hospitals segment expected to held the largest share

• Based on the application, hospitals are expected to dominate the cell therapy market since it is gradually embracing the adoption of innovative treatment procedures. Billions of dollar are spent annually on cell therapies and hospitals are central to delivering cell treatments given the infrastructure, knowledge and care management for patients receiving cell therapies. More people are being diagnosed with chronic diseases requiring advanced treatment, and the development of complicated therapies has made cell therapies integrate into hospitals more easily. Furthermore, the largest contribution in the market is expected to be seen from the hospital specialties, as hospitals are more focused on developing better technologies and infrastructure to safely deliver cell therapies in a more efficient manner as compared to other industry players. With ongoing changes in the healthcare systems worldwide, the hospital segment is anticipated to continue being a key growth segment in the cell therapy market.

Cell Therapy Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• According to analysis by reports in the year 2023, North America contributed nearly 40% toward the global cell therapy market share. There are many reasons for this leadership; favorable healthcare resources, high research spending, and concentration of key players. The United States stands out as the most progressive region in cell therapy due to the several clinical trials, approval of regenerative therapies and the breakthrough therapies available in the region. In addition, chronic diseases are becoming more common, and patients’ demand for better treatment is building, which contributes to the growth of cell therapies. North America cell therapy market is set to grow further owing to the favourable regulatory environment and continuation of the patronization between academic institutions and the biotechnology market.

Active Key Players in the Cell Therapy Market

• Astellas Pharma Inc. (Japan)
• bluebird bio, Inc. (USA)
• Celgene Corporation (USA)
• Gilead Sciences, Inc. (USA)
• Juno Therapeutics, Inc. (USA)
• Mesoblast Limited (Australia)
• Novartis AG (Switzerland)
• Organogenesis Holdings Inc. (USA)
• Takeda Pharmaceutical Company Limited (Japan), Other key Players.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Cell Therapy Market by Type
 4.1 Cell Therapy Market Snapshot and Growth Engine
 4.2 Cell Therapy Market Overview
 4.3 Autologous Therapies
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Autologous Therapies: Geographic Segmentation Analysis
 4.4 Allogenic Therapies
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Allogenic Therapies: Geographic Segmentation Analysis

Chapter 5: Cell Therapy Market by End User
 5.1 Cell Therapy Market Snapshot and Growth Engine
 5.2 Cell Therapy Market Overview
 5.3 Hospitals
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Hospitals: Geographic Segmentation Analysis
 5.4 Diagnostic centers
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Diagnostic centers: Geographic Segmentation Analysis
 5.5 Clinics
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Clinics: Geographic Segmentation Analysis
 5.6 Research institutes
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Research institutes: Geographic Segmentation Analysis
 5.7 Regenerative medicine centers
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Regenerative medicine centers: Geographic Segmentation Analysis
 5.8 Others
  5.8.1 Introduction and Market Overview
  5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.8.3 Key Market Trends, Growth Factors and Opportunities
  5.8.4 Others: Geographic Segmentation Analysis

Chapter 6: Company Profiles and Competitive Analysis
 6.1 Competitive Landscape
  6.1.1 Competitive Benchmarking
  6.1.2 Cell Therapy Market Share by Manufacturer (2023)
  6.1.3 Industry BCG Matrix
  6.1.4 Heat Map Analysis
  6.1.5 Mergers and Acquisitions
  
 6.2 ASTELLAS PHARMA INC (JAPAN)
  6.2.1 Company Overview
  6.2.2 Key Executives
  6.2.3 Company Snapshot
  6.2.4 Role of the Company in the Market
  6.2.5 Sustainability and Social Responsibility
  6.2.6 Operating Business Segments
  6.2.7 Product Portfolio
  6.2.8 Business Performance
  6.2.9 Key Strategic Moves and Recent Developments
  6.2.10 SWOT Analysis
 6.3 BLUEBIRD BIO INC (USA)
 6.4 CELGENE CORPORATION (USA)
 6.5 GILEAD SCIENCES INC (USA)
 6.6 JUNO THERAPEUTICS INC (USA)
 6.7 MESOBLAST LIMITED (AUSTRALIA)
 6.8 NOVARTIS AG (SWITZERLAND)
 6.9 ORGANOGENESIS HOLDINGS INC (USA)
 6.10 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JAPAN)
 6.11 OTHER KEY PLAYERS

Chapter 7: Global Cell Therapy Market By Region
 7.1 Overview
 7.2. North America Cell Therapy Market
  7.2.1 Key Market Trends, Growth Factors and Opportunities
  7.2.2 Top Key Companies
  7.2.3 Historic and Forecasted Market Size by Segments
  7.2.4 Historic and Forecasted Market Size By Type
  7.2.4.1 Autologous Therapies
  7.2.4.2 Allogenic Therapies
  7.2.5 Historic and Forecasted Market Size By End User
  7.2.5.1 Hospitals
  7.2.5.2 Diagnostic centers
  7.2.5.3 Clinics
  7.2.5.4 Research institutes
  7.2.5.5 Regenerative medicine centers
  7.2.5.6 Others
  7.2.6 Historic and Forecast Market Size by Country
  7.2.6.1 US
  7.2.6.2 Canada
  7.2.6.3 Mexico
 7.3. Eastern Europe Cell Therapy Market
  7.3.1 Key Market Trends, Growth Factors and Opportunities
  7.3.2 Top Key Companies
  7.3.3 Historic and Forecasted Market Size by Segments
  7.3.4 Historic and Forecasted Market Size By Type
  7.3.4.1 Autologous Therapies
  7.3.4.2 Allogenic Therapies
  7.3.5 Historic and Forecasted Market Size By End User
  7.3.5.1 Hospitals
  7.3.5.2 Diagnostic centers
  7.3.5.3 Clinics
  7.3.5.4 Research institutes
  7.3.5.5 Regenerative medicine centers
  7.3.5.6 Others
  7.3.6 Historic and Forecast Market Size by Country
  7.3.6.1 Bulgaria
  7.3.6.2 The Czech Republic
  7.3.6.3 Hungary
  7.3.6.4 Poland
  7.3.6.5 Romania
  7.3.6.6 Rest of Eastern Europe
 7.4. Western Europe Cell Therapy Market
  7.4.1 Key Market Trends, Growth Factors and Opportunities
  7.4.2 Top Key Companies
  7.4.3 Historic and Forecasted Market Size by Segments
  7.4.4 Historic and Forecasted Market Size By Type
  7.4.4.1 Autologous Therapies
  7.4.4.2 Allogenic Therapies
  7.4.5 Historic and Forecasted Market Size By End User
  7.4.5.1 Hospitals
  7.4.5.2 Diagnostic centers
  7.4.5.3 Clinics
  7.4.5.4 Research institutes
  7.4.5.5 Regenerative medicine centers
  7.4.5.6 Others
  7.4.6 Historic and Forecast Market Size by Country
  7.4.6.1 Germany
  7.4.6.2 UK
  7.4.6.3 France
  7.4.6.4 Netherlands
  7.4.6.5 Italy
  7.4.6.6 Russia
  7.4.6.7 Spain
  7.4.6.8 Rest of Western Europe
 7.5. Asia Pacific Cell Therapy Market
  7.5.1 Key Market Trends, Growth Factors and Opportunities
  7.5.2 Top Key Companies
  7.5.3 Historic and Forecasted Market Size by Segments
  7.5.4 Historic and Forecasted Market Size By Type
  7.5.4.1 Autologous Therapies
  7.5.4.2 Allogenic Therapies
  7.5.5 Historic and Forecasted Market Size By End User
  7.5.5.1 Hospitals
  7.5.5.2 Diagnostic centers
  7.5.5.3 Clinics
  7.5.5.4 Research institutes
  7.5.5.5 Regenerative medicine centers
  7.5.5.6 Others
  7.5.6 Historic and Forecast Market Size by Country
  7.5.6.1 China
  7.5.6.2 India
  7.5.6.3 Japan
  7.5.6.4 South Korea
  7.5.6.5 Malaysia
  7.5.6.6 Thailand
  7.5.6.7 Vietnam
  7.5.6.8 The Philippines
  7.5.6.9 Australia
  7.5.6.10 New Zealand
  7.5.6.11 Rest of APAC
 7.6. Middle East & Africa Cell Therapy Market
  7.6.1 Key Market Trends, Growth Factors and Opportunities
  7.6.2 Top Key Companies
  7.6.3 Historic and Forecasted Market Size by Segments
  7.6.4 Historic and Forecasted Market Size By Type
  7.6.4.1 Autologous Therapies
  7.6.4.2 Allogenic Therapies
  7.6.5 Historic and Forecasted Market Size By End User
  7.6.5.1 Hospitals
  7.6.5.2 Diagnostic centers
  7.6.5.3 Clinics
  7.6.5.4 Research institutes
  7.6.5.5 Regenerative medicine centers
  7.6.5.6 Others
  7.6.6 Historic and Forecast Market Size by Country
  7.6.6.1 Turkey
  7.6.6.2 Bahrain
  7.6.6.3 Kuwait
  7.6.6.4 Saudi Arabia
  7.6.6.5 Qatar
  7.6.6.6 UAE
  7.6.6.7 Israel
  7.6.6.8 South Africa
 7.7. South America Cell Therapy Market
  7.7.1 Key Market Trends, Growth Factors and Opportunities
  7.7.2 Top Key Companies
  7.7.3 Historic and Forecasted Market Size by Segments
  7.7.4 Historic and Forecasted Market Size By Type
  7.7.4.1 Autologous Therapies
  7.7.4.2 Allogenic Therapies
  7.7.5 Historic and Forecasted Market Size By End User
  7.7.5.1 Hospitals
  7.7.5.2 Diagnostic centers
  7.7.5.3 Clinics
  7.7.5.4 Research institutes
  7.7.5.5 Regenerative medicine centers
  7.7.5.6 Others
  7.7.6 Historic and Forecast Market Size by Country
  7.7.6.1 Brazil
  7.7.6.2 Argentina
  7.7.6.3 Rest of SA

Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies

Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research